| Literature DB >> 30430043 |
Abstract
BACKGROUND: Cystic fibrosis (CF) is a disease characterized by chronic airway infection with a high incidence and poor prognosis. Pseudomonas aeruginosa and Aspergillus fumigatus are pathogens commonly found in CF patients. Clinically, these two microorganisms often coexist in the airway of CF patients. Combined infection with P. aeruginosa and A. fumigatus results in worsening lung function and clinical condition.Entities:
Keywords: Aspergillus fumigatus; Cystic fibrosis; Infection; Intermicrobial interaction; Pseudomonas aeruginosa
Year: 2018 PMID: 30430043 PMCID: PMC6231424 DOI: 10.7717/peerj.5931
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Figure 1Model for the interaction between P. aeruginosa and A. fumigatus.
Arrows indicate promotion. Arrows without heads indicate inhibition. Blue lines indicate the effect of P. aeruginosa on A. fumigatus. Red lines indicate the effect of A. fumigatus on P. aeruginosa. Pathway ① indicates the effect of P. aeruginosa on A. fumigatus by phenazine. PYO, PCA, PCN, and 1-HP inhibit A. fumigatus growth by inducing the production of ROS and RNS. Sub-MIC PYO, PCA, PCN, and 1-HP promote A. fumigatus growth by iron absorption. A. fumigatus growth can be inhibited by diRhls, which blocks β1,3 GS activity. Pathway ② shows the effect of A. fumigatus on P. aeruginosa by phenazine transformation. The metabolic conversion of phenazine by A. fumigatus inhibits the reduction of Fe3+ and affects QS system regulation in P. aeruginosa. Pathway ③ depicts the inhibition of toxic products and small molecules regulated by the QS system. The QS system in P. aeruginosa inhibits A. fumigatus growth via the effect of diRhls, PQS, and 3-oxo-C12 HSL. Pathway ④ shows that P. aeruginosa inhibits A. fumigatus growth via the effect of pyoverdine, Pf4, and SVSs on A. fumigatus iron deprivation. Pathway ⑤ and Pathway ⑥ illustrate P. aeruginosa promotion of A. fumigatus growth through the inhibition of host immune components and emission of VOCs. Pathway ⑦ shows that gliotoxin produced by A. fumigatus interferes with the metabolic growth of P. aeruginosa. Pathway ⑧ shows that A. fumigatus reduces the sensitivity of P. aeruginosa to antibiotics and promotes chronic infection.
Figure 2Model for the interaction between P. aeruginosa and A. fumigatus by iron uptake and competition.
Pyoverdine and Pf4 phage bind to Fe3+ and promote uptake by P. aeruginosa. Pyoverdine and Pf4 phage deprive A. fumigatus of Fe3+ and inhibit its growth (pathway ①). Phenazine reduces Fe3+ to Fe2+ and promotes P. aeruginosa uptake of Fe2+. Phenazine is converted by A. fumigatus into metabolic products with potentially modified redox potentials. These products may inhibit the reduction of Fe3+ in P. aeruginosa (pathway ②). Sub-MIC PYO, PCN, and PCA reduce Fe3+ to Fe2+ and promote the FetCp/FtrA complex of A. fumigatus to take up Fe2+ (pathway ③). Sub-MIC 1-HP reduces Fe3+ to Fe2+, and two 1-HP molecules bind the newly formed Fe2+. This chelating activity induces iron starvation and activates triacetylfusarinine C (TAFC). TAFC promotes A. fumigatus uptake of Fe3+ and stimulates its growth (pathway ④).